CIA’s Venture Capital Arm Is Funding Skin Care Products That Collect DNA

SKINCENTIAL SCIENCES, a company with an innovative line of cosmetic products marketed as a way to erase blemishes and soften skin, has caught the attention of beauty bloggers on YouTube, Oprah’s lifestyle magazine, and celebrity skin care professionals. Documents obtained by The Intercept reveal that the firm has also attracted interest and funding from In-Q-Tel, the venture capital arm of the Central Intelligence Agency.

The previously undisclosed relationship with the CIA might come as some surprise to a visitor to the website of Clearista, the main product line of Skincential Sciences, which boasts of a “formula so you can feel confident and beautiful in your skin’s most natural state.”

Though the public-facing side of the company touts a range of skin care products, Skincential Sciences developed a patented technology that removes a thin outer layer of the skin, revealing unique biomarkers that can be used for a variety of diagnostic tests, including DNA collection.

Skincential Science’s noninvasive procedure, described on the Clearista website as “painless,” is said to require only water, a special detergent, and a few brushes against the skin, making it a convenient option for restoring the glow of a youthful complexion — and a novel technique for gathering information about a person’s biochemistry.

In-Q-Tel, founded in 1999 by then-CIA Director George Tenet, identifies cutting-edge technology to support the mission of the CIA and other intelligence agencies and provides venture funding to help grow tech firms to develop those solutions.

Our company is an outlier for In-Q-Tel,” Russ Lebovitz, the chief executive of Skincential Sciences, said during an interview with The Intercept. He conceded that the relationship might make for “an unusual and interesting story,” but said, “If there’s something beneath the surface, that’s not part of our relationship and I’m not directly aware. They’re interested here in something that can get easy access to biomarkers.”Still, Lebovitz claimed he has limited knowledge of why In-Q-Tel selected his firm.

Read the Whole Article